TABLE 2:

Results of proton MR spectroscopy in parieto-occipital white matter and gray matter

A: Patients’ last investigations
PatientNo. of StudiesAge Range, yearWhite Matter Lipid Peak, auWhite Matter Metabolites, mmol/L
t-NAACrChoInsGlx
130.8–15.79.54.92.33.011.6
250.4–43.09.54.71.54.69.8
323–527.811.15.42.48.110.5
41823.411.16.02.15.313.6
51811.28.54.82.04.08.6
625–915.510.16.11.85.113.4
726–91.911.36.12.15.811.3
81921.39.35.82.46.610.6
947–1011.511.45.21.94.014.3
10110Present
1111311.29.44.71.85.98.7
12311–1413.69.96.32.16.013.0
13412–1619.811.96.02.06.310.2
14217–1720.310.56.61.86.716.0
15315–178.612.76.81.95.415.3
16221–216.911.07.62.45.514.5
181451.68.96.01.83.69.8
B: Group means and standard deviations
GroupLipid Peak, auMetabolites, mmol/L
t-NAACrChoInsGlx
White matter
 Patients (n = 16)12.7 (8.1)*10.4 (1.2)5.8 (0.8)2.0 (0.3)5.4 (1.3)§12.0 (2.4)
 Control subjects (n = 9)0.6 (0.6)9.6 (0.9)5.1 (0.3)1.7 (0.3)3.5 (1.0)12.4 (0.9)
Gray matter
 Patients (n = 15)0.9 (0.8)11.2 (1.6)7.1 (1.0)1.5 (0.3)3.9 (1.6)17.0 (2.7)
 Control subjects (n = 9)1.1 (0.8)11.1 (0.5)6.5 (0.5)1.4 (0.1)4.3 (0.8)15.6 (2.0)
  • Note.—au = arbitrary units, t-NAA = total NAA (N-acetylaspartate and N-acetylaspartylglutamate), Cr = creatine and creatine phosphate, Cho = free choline and the choline-containing compounds phosphocholine and glycerophosphorylcholine, Ins = myo-inositol, Glx = glutamine and glutamate, dashes = no data available. P values are given when P < .05 for SLS patients compared with healthy control subjects (unpaired two-tailed t test).

  • * P = .0002.

  • P = .02.

  • P = .005.

  • § P = .001.